Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
Authors
Keywords
-
Journal
Clinical & Developmental Immunology
Volume 2012, Issue -, Pages 1-12
Publisher
Hindawi Limited
Online
2012-06-02
DOI
10.1155/2012/124187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Evaluation of Current Cancer Immunotherapy
- (2011) Christopher S. Hourigan et al. CANCER JOURNAL
- Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
- (2011) S. R. Mattarollo et al. CANCER RESEARCH
- Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice
- (2011) S. Gingis-Velitski et al. CANCER RESEARCH
- Chemotherapy Enhances Metastasis Formation via VEGFR-1-Expressing Endothelial Cells
- (2011) L. G. M. Daenen et al. CANCER RESEARCH
- Tumor Immunology: Basic and Clinical Advances
- (2011) P. L. Beatty et al. CANCER RESEARCH
- Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide
- (2011) F. Moschella et al. CANCER RESEARCH
- Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
- (2011) A. M. Lesokhin et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
- (2011) Mikayel Mkrtichyan et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic Chemoimmunotherapy Achieves Cure of Spontaneous Murine Mammary Tumors via Persistent Blockade of Posttherapy Counter-Regulation
- (2011) Rachael B. Rowswell-Turner et al. JOURNAL OF IMMUNOLOGY
- Type I IFNs Control Antigen Retention and Survival of CD8 + Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming
- (2011) S. Lorenzi et al. JOURNAL OF IMMUNOLOGY
- IL-1 and IL-1 Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
- (2011) P. Rider et al. JOURNAL OF IMMUNOLOGY
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy
- (2011) Enrico Proietti et al. Molecular Oncology
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
- (2011) Antonella Sistigu et al. Seminars in Immunopathology
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
- (2011) Ole Audun Werner Haabeth et al. Nature Communications
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma
- (2010) C. Xuan et al. BLOOD
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
- (2010) Kavya Rakhra et al. CANCER CELL
- Immune Regulatory Antibodies
- (2010) Jedd D. Wolchok et al. CANCER JOURNAL
- Chemoimmunotherapy
- (2010) Leisha A. Emens CANCER JOURNAL
- Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model
- (2010) A. Sharabi et al. Cancer Prevention Research
- Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
- (2010) S. Viaud et al. CANCER RESEARCH
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
- (2010) R. Bos et al. CANCER RESEARCH
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
- (2010) B. D. Smith et al. CLINICAL CANCER RESEARCH
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
- (2010) M. J. Besser et al. CLINICAL CANCER RESEARCH
- A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2
- (2010) Silvia Piconese et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- APC Activation by IFN- Decreases Regulatory T Cell and Enhances Th Cell Functions
- (2010) L. Pace et al. JOURNAL OF IMMUNOLOGY
- IL-1 -Mediated Signals Preferentially Drive Conversion of Regulatory T Cells but Not Conventional T Cells into IL-17-Producing Cells
- (2010) L. Li et al. JOURNAL OF IMMUNOLOGY
- IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells
- (2010) Donggou He et al. JOURNAL OF IMMUNOLOGY
- Cancer and Inflammation: Promise for Biologic Therapy
- (2010) Sandra Demaria et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
- (2010) M. J. P. Welters et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation
- (2009) I. Horkheimer et al. BLOOD
- CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas
- (2009) E. A. Rossi et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- Central Role of IFN -Indoleamine 2,3-Dioxygenase Axis in Regulation of Interleukin-12-Mediated Antitumor Immunity
- (2009) T. Gu et al. CANCER RESEARCH
- Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy
- (2009) J. Kohlmeyer et al. CANCER RESEARCH
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
- (2009) M. B. Faries et al. CLINICAL CANCER RESEARCH
- Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
- (2009) B. B. Aggarwal et al. CLINICAL CANCER RESEARCH
- Partial CD4 Depletion Reduces Regulatory T Cells Induced by Multiple Vaccinations and Restores Therapeutic Efficacy
- (2009) M. G. LaCelle et al. CLINICAL CANCER RESEARCH
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
- (2009) C. L. Slingluff et al. CLINICAL CANCER RESEARCH
- PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV
- (2009) Debora Franceschini et al. JOURNAL OF CLINICAL INVESTIGATION
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation
- (2009) A. J. Currie et al. JOURNAL OF IMMUNOLOGY
- IFN- Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity
- (2009) A. G. Sikora et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right
- (2009) C. E. Ruby et al. JOURNAL OF IMMUNOLOGY
- Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies
- (2009) Marc Pellegrini et al. NATURE MEDICINE
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
- (2009) François Ghiringhelli et al. NATURE MEDICINE
- IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation
- (2009) S. Z. Ben-Sasson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
- (2009) J. M. Weiss et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors
- (2008) J. D. Brody et al. BLOOD
- Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT
- (2008) A. L. Bayer et al. BLOOD
- CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
- (2008) B. Kavanagh et al. BLOOD
- Induction of Cancer Metastasis by Cyclophosphamide Pretreatment of Host Mice: An Opposite Effect of Chemotherapy
- (2008) K. Yamauchi et al. CANCER RESEARCH
- Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy?
- (2008) Ron N. Apte et al. IMMUNOLOGICAL REVIEWS
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
- (2008) Francisco J. Quintana et al. NATURE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
- (2008) H Conroy et al. ONCOGENE
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started